EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions

Dong-Wan Kim iD, Alison M Schram, Antoine Hollebecque, Kazumi Nishino, Teresa Macarulla, Sun Young Rha, Michaël Duruisseaux, Stephen V Liu, Mohammed Najeeb Al Hallak, Kumiko Umemoto, Claas Wesseler, James M Cleary und 6 weitere

Future Oncology · 2024

DOI: 10.2217/fon-2023-0824 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, 2024. Verfasst von Dong-Wan Kim und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University College of Medicine & Seoul National University Hospital, Seoul, 03080, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Neuregulin-1. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Merus NV.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuregulin 1 (NRG1) fusions are oncogenic drivers that have been detected in non-small-cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. NRG1 fusions are rare, occurring in less than 1% of solid tumors. Patients with NRG1 fusion positive (NRG1+) cancer have limited therapeutic options. Zenocutuzumab is a novel, bispecific IgG1 antibody that targets both HER2 and HER3 proteins and inhibits NRG1 binding through a 'Dock & Block®' mechanism of action. Here, we describe the rationale and design of the phase II component of the eNRGy trial, part of the overall, open-label phase I/II, multicenter trial exploring the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and antitumor activity of zenocutuzumab in patients with NRG1+ NSCLC, PDAC or other solid tumors. eNRGy: a clinical trial of zenocutuzumab for cancer caused by NRG1 gene fusionsNRG1 gene fusions are rare mutations that cause cancer cells to grow. These fusions are found in many different types of cancer. Tumors with NRG1 gene fusions do not respond well to standard treatment options. Zenocutuzumab, or Zeno, is a treatment that is being tested to see if it can stop cancer that is growing because of NRG1 gene fusions. Here, we describe the reasoning for and design of an ongoing clinical trial (eNRGy) designed to study the efficacy (how well it works) and safety of Zeno in patients with cancer that has NRG1 gene fusions. The eNRGy trial is recruiting patients with cancer that has NRG1 gene fusions, including non-small-cell lung cancer, pancreatic cancer and others. Patients who join this trial will receive Zeno once every 2 weeks until their cancer grows. The main goal (primary end point) of this trial is to determine the percentage of patients whose tumors decrease in size by 30% or more. The eNRGy trial is currently enrolling patients. For more information, refer to ClinicalTrials.gov (Identifier: NCT02912949), visit https://nrg1.com/, or call 1-833-NRG-1234.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungNeuregulin-1AdultFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCarcinoma, Pancreatic DuctalLung NeoplasmsNeoplasmsOncogene Proteins, FusionErb-b2 Receptor Tyrosine KinasesReceptor, ErbB-3Clinical Trials, Phase I as TopicClinical Trials, Phase II as TopicMulticenter Studies as Topic

Stichwörter der Autor:innen

HER2HER3NRG1 fusionNRG1+NSCLCPDACZenoZenocutuzumabeNRGy trialrecruiting

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalNeuregulin-1Oncogene Proteins, FusionErb-b2 Receptor Tyrosine KinasesReceptor, ErbB-3NRG1 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University College of Medicine & Seoul National University Hospital, Seoul, 03080, Republic of Korea.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Drug Development (DITEP), GI Oncology, Gustave Roussy Cancer Campus, Villejuif, 94805, France.
  • Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, 540-0008, Japan.
  • Gastrointestinal and Endocrine Tumor Unit, Vall d´Hebrón University Hospital, Vall d´Hebrón Institute of Oncology (VHIO), Barcelona, 08035, Spain.
  • Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, 03722, Republic of Korea.

ORCID-Profile: Dong-Wan Kim

Förderung

  • NCI NIH HHS
  • Merus NV

Zitieren

APA

Kim, D. W., Schram, A. M., Hollebecque, A., Nishino, K., Macarulla, T., Rha, S. Y., Duruisseaux, M., Liu, S. V., Al Hallak, M. N., Umemoto, K., Wesseler, C., Cleary, J. M., Springfeld, C., Neuzillet, C., Joe, A., Jauhari, S., Ford, J., & Goto, K. (2024). The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions. Future Oncology. https://doi.org/10.2217/fon-2023-0824

Vancouver

Kim DW, Schram AM, Hollebecque A, Nishino K, Macarulla T, Rha SY, et al. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions. Future Oncology. 2024. doi:10.2217/fon-2023-0824

BibTeX
@article{Kim2024,
  author = {Kim, Dong-Wan and Schram, Alison M and Hollebecque, Antoine and Nishino, Kazumi and Macarulla, Teresa and Rha, Sun Young and Duruisseaux, Michaël and Liu, Stephen V and Al Hallak, Mohammed Najeeb and Umemoto, Kumiko and Wesseler, Claas and Cleary, James M and Springfeld, Christoph and Neuzillet, Cindy and Joe, Andrew and Jauhari, Shekeab and Ford, Jim and Goto, Koichi},
  title = {The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions},
  journal = {Future Oncology},
  year = {2024},
  doi = {10.2217/fon-2023-0824}
}
Kostenlos starten →